NSE · KOPRAN
Kopran Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹63 Cr with net profit ₹7 Cr — a 10.71% net margin, versus 3.77% the period before.
Shareholding
As of 2026-06-30
- Promoter44.42%
- Public55.06%
- FII0.51%
- DII0%
56,925 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.37× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #54 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,516 Cr | 35.34 | 5.35 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,501 Cr | 22.84 | 4.11 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,943 Cr | 31 | 3.24 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,091 Cr | 96.1 | 19.74 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹95,996 Cr | 25.39 | 2.53 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,404 Cr | 29.61 | 2.5 | 11.07% | 9.73% |
| Lupin Limited | ₹95,011 Cr | 15.95 | 4.23 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,456 Cr | 43.34 | 5.69 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,157 Cr | 21.84 | 6.49 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,558 Cr | 87.05 | 1.84 | 1.14% | 2.89% |
| Kopran Ltd.(this company) | ₹1,139 Cr | 45.61 | 2.15 | 4.85% | 3.57% |
AI analysis
AI-generated · google/gemini-2.5-flashKopran Ltd. has a market capitalization of Rs 981 Cr. The company's revenue for the last reported fiscal year was Rs 633.59 Cr, with a profit margin of 377.7%. The stock's 52-week high is Rs 219 and its 52-week low is Rs 107.
Positives
- +The company reported a high Return on Equity (ROE) of 485.2%.
- +Kopran Ltd. has a high profit margin of 377.7%.
- +The debt-to-equity ratio is low at 0.24.
- +Promoter pledge is 0%, indicating no shares pledged by the promoters.
Negatives
- −Revenue growth for the fiscal year ending March 2025 was 2.4%, which is relatively low.
- −Quarterly net profit declined to -9.92 Cr in September 2025.
- −The company is under ESM surveillance (ESM · ESM 1).
- −Dividend yield is exceptionally high at 147%; this figure may indicate a data error or a one-time special dividend.
Financial performance
For the fiscal year ending March 2025, Kopran Ltd. reported revenue of Rs 633.59 Cr, representing a 2.4% revenue growth. Net profit for the same period was Rs 38.55 Cr, and EPS stood at Rs 7.99. In the latest quarterly results (Mar 2026), revenue was Rs 234.02 Cr and net profit was Rs 18.87 Cr.
Profitability & returns
The company reported a profit margin of 377.7%. The Return on Equity (ROE) is 485.2%, and the Return on Capital Employed (ROCE) is 6.56%. The earnings per share (EPS) for the fiscal year ending March 2025 was Rs 7.99.
Balance sheet
Kopran Ltd. has a book value per share of Rs 109.82. The company's debt-to-equity ratio is 0.24, indicating a relatively low level of debt compared to equity. No information on current assets or liabilities is available.
Ownership & pledges
As of June 30, 2026, promoter holding in Kopran Ltd. stood at 44.422%, while public shareholding was 55.06%. Foreign Institutional Investors (FIIs) held 0.5135% of shares, and Domestic Institutional Investors (DIIs) held 0.0045%. There were no promoter pledges reported (0%).
Regulatory & surveillance
Kopran Ltd. is currently under the Exchange Surveillance Measure (ESM) framework, specifically 'ESM · ESM 1'.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.